A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs LXH 254 (Primary) ; PDR 001
- Indications Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 30 Jun 2017 Planned number of patients changed from 126 to 174.
- 17 Mar 2017 Planned End Date changed from 28 Jul 2018 to 14 Mar 2019.
- 17 Mar 2017 Planned primary completion date changed from 28 Jul 2018 to 14 Mar 2019.